BPC-157

Also known as Body Protection Compound-157 · PL-14736 · Bepecin

Pentadecapeptide — A synthetic pentadecapeptide derived from a gastric protein sequence. Supplied as a reference standard for in-vitro angiogenesis, cell-migration and tissue-model research.

Latest released COA: 99.487%Lyophilized powder

Available vial sizes

10 mg$42.99In stock

From $42.99In stock

View purchase options

Specifications

CAS number	137525-51-0
Molecular formula	C62H98N16O22
Molecular weight	1419.56 g/mol
Form	Lyophilized powder

Research use only. Not for human or veterinary use, consumption, diagnosis, treatment, or therapeutic purposes.

Documentation

Certificates of Analysis

Batch-specific, third-party lab certificates. Each COA is published here once its lot has been tested — preview the results, then open the full PDF.

Current released record

AST-BP10-001

Dosage: 10 mg
Purity: 99.487%
Laboratory: Janoshik Analytical
Analyzed: 2026-05-11

Open source PDF

View the compound COA record →

More to explore

View all

Research context

BPC-157 research, identity and references

Also known as Body Protection Compound-157, PL-14736, Bepecin

What kind of evidence exists for BPC-157?

Published BPC-157 literature is predominantly preclinical, including cell and animal models. Astral presents that boundary explicitly: cited mechanisms and model findings are not proof of human safety, efficacy, or a permitted use.

CAS number137525-51-0

Molecular formulaC62H98N16O22

Molecular weight1419.56 g/mol

SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Animal and cell-culture study

Animal and cell-culture study
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.
Chang CH, Tsai WC, Lin MS, et al. Journal of Applied Physiology (2011).
Examines tendon-derived cell outgrowth and migration in experimental models. Model findings do not translate to human use.
PMID 21030672 · DOI 10.1152/japplphysiol.00945.2010

In vitro and animal study

In vitro and animal study
Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.
Huang T, Zhang K, Sun L, et al. Drug Design, Development and Therapy (2015).
Examines cell migration and angiogenesis in experimental models; it does not establish human outcomes.
PMID 25995620 · DOI 10.2147/DDDT.S82030

Literature review

Literature review
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.
Gwyer D, Wragg NM, Wilson SL. Cell and Tissue Research (2019).
Reviews preclinical soft-tissue literature and highlights the limited translation boundary.
PMID 30915550 · DOI 10.1007/s00441-019-03016-8

Scientific review

Scientific review
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
Seiwerth S, Milavic M, Vukojevic J, et al. Frontiers in Pharmacology (2021).
Surveys the preclinical wound-healing literature for this peptide. It is a review of animal and cell work, not evidence of a human outcome or of any Astral lot.
PMID 34267654 · DOI 10.3389/fphar.2021.627533

Systematic review

Systematic review
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Vasireddi N, Hahamyan H, Salata MJ, et al. HSS Journal (2025).
A recent systematic appraisal of the evidence base and its limits. Included here because it states the translation boundary plainly rather than to imply an application.
PMID 40756949 · DOI 10.1177/15563316251355551

Editorially curated and source-verified; not independently peer-reviewed by Astral. Last source check: 2026-08-04. How sources are selected.

Check released lot evidence →